サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1297809

リキッドバイオプシーの世界市場-2023年～2030年

Global Liquid Biopsy Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
リキッドバイオプシーの世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のリキッドバイオプシー市場は、2022年に41億米ドルに達し、2030年には123億米ドルに達し、有利な成長が予測されています。リキッドバイオプシーの世界市場は、予測期間2023-2030年に15.4%のCAGRを示すと予測されます。

リキッドバイオプシーは、体液中のバイオマーカーを分析する非侵襲的診断技術であり、がんなどの様々な疾患に関する知見を提供します。従来の組織生検に比べ、サンプル採取が容易であり、リアルタイムでの疾患モニタリングが可能であるなどの利点があります。

さらに、世界のがんの有病率の増加、ゲノム研究と技術の進歩、低侵襲診断手順の採用の増加、疾患の早期発見とモニタリングの可能性の高まりが、予測期間にわたって市場を牽引すると予想されます。

市場力学

固形がんの小児を対象としたリキッドバイオプシー調査の増加がリキッドバイオプシー市場の成長を促進する見込み

National Cancer Institute Article 2023によると、がん分野の研究者はリキッドバイオプシー検査の開発を進めており、従来の組織生検を補完、あるいは代替する可能性があります。

これらの検査は、腫瘍が血流やその他の体液中に放出する遺伝子やその他の物質を分析するものです。現在、リキッドバイオプシーは、がんに関連した遺伝子変化を検出し、治療の意思決定に役立てるために利用されています。

科学者たちは、ユーイング肉腫、骨肉腫、ウィルムス腫瘍（腎臓がん）などの固形がんに焦点を当て、小児がんにもリキッドバイオプシーの研究を拡大しています。ロサンゼルス小児病院（CHLA）と南カリフォルニア大学の研究者による最近の調査で、小児がん患者専用のリキッドバイオプシー検査の開発が進展しました。

この検査は血液サンプルに含まれるDNA断片を分析するもので、小児の様々なタイプの固形腫瘍の診断に有望な結果を示しています。npj Precision Oncology誌に掲載されたこの研究はまた、初回治療成功後の治療反応性の評価や腫瘍再発の可能性の検出におけるこの検査の可能性を示しています。

CHLAとUSCの研究開発者が開発したリキッドバイオプシー検査は、ローパス全ゲノムシーケンスを用いたコピー数変化の検出に焦点を当てています。この方法はコスト効率がよく、複数のサンプルを同時に解析できます。

一塩基の変化も検出できるが、すべてを検出することはできないです。小児用に開発されている多くのリキッドバイオプシーとは異なり、このアプローチや他の研究者による同様の検査は、複数のタイプのがんを同定することを目的としています。したがって、上記の要因により、予測期間中に市場は拡大すると予想されます。

がん診断における新たなツールの開拓がリキッドバイオプシー市場の成長を牽引する見込み

Fred Hutchinson Cancer Centerの計算生物学者Gavin Ha博士は、2022年National Institutes of Health Director's New イノベーター Awardを受賞した。この150万米ドルの5年間の助成金は、リキッドバイオプシーに含まれる無細胞の腫瘍DNAを活用し、がんの診断、治療法の選択、疾患のモニタリングのための貴重な情報を収集するHa氏の研究を支援するものです。リキッドバイオプシーは、血液サンプルに含まれるDNAの痕跡を分析するもので、腫瘍に関する分子学的洞察を提供します。

ほとんどのリキッドバイオプシーでは、がんに関連したDNA配列の変化を検出することに重点を置いているが、Haは、DNA断片が血流中で持続するための要因を調査し、特にDNAパッケージング・タンパク質による保護を調べることで、異なるアプローチをとっています。私たちの細胞内のDNAはコンパクトにパッケージングされており、このパッケージングが遺伝子制御に一役買っています。遺伝子の発現は、がん細胞の治療に対する反応、抵抗性パターン、異なるがん細胞への変容の可能性に影響を与えます。

リキッドバイオプシーにおける技術的課題と限界が世界のリキッドバイオプシー市場の成長を妨げる

リキッドバイオプシー技術は、その有効性を制限し市場成長を妨げる様々な技術的課題に直面しています。これらの課題には、感度と特異性、標準化、再現性などがあります。

加えて、規制や償還の問題はリキッドバイオプシー検査の普及を妨げる可能性があります。これらの課題には、規制当局の承認や償還政策が含まれます。したがって、上記の要因から、予測期間中、市場は阻害されると予想されます。

COVID-19影響分析

COVID-19パンデミックはリキッドバイオプシー市場に大きな影響を与えました。パンデミックの間、がん検診や診断処置を含む定期的なヘルスケア受診が減少しました。

その結果、リキッドバイオプシー検査は従来の組織生検に代わる非侵襲的な検査として用いられることが多いため、需要が影響を受けた可能性があります。患者の受診や診断検査の減少により、リキッドバイオプシー技術の採用や利用が全体的に減少したと思われます。

さらに、リキッドバイオプシーの研究開発に関連する進行中の臨床試験の多くが、パンデミックにより遅延や中断を経験しています。患者募集の制限、ヘルスケア施設へのアクセスの制限、COVID-19管理のためのリソースの優先順位付けなどが、臨床試験のスケジュールの延期や変更につながっています。このような調査活動の遅れは、新しいリキッドバイオプシー技術や製品の市場導入に影響を与える可能性があります。

パンデミックの進展とヘルスケアシステムの適応に伴い、リキッドバイオプシー市場は回復し、技術や調査の進歩、個別化された非侵襲的がん診断への需要の高まりによって成長軌道を継続すると予想されます。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、ヘルスケア産業や潜在的にリキッドバイオプシー市場を含む様々な分野に影響を及ぼしています。戦争は影響を受けた地域、特にウクライナのヘルスケア・インフラに大きな中断をもたらしました。医療施設の損傷、医療供給不足、医療スタッフの移転はすべて、医療システムの日常的な運営を妨げる可能性があります。

医療資源がより緊急の医療ニーズに対応するために振り向けられる中、この中断は、リキッドバイオプシーを含む多くの診断検査の入手可能性や利用しやすさに影響を及ぼす可能性があります。さらに、戦争とその経済的影響は、医療支出と優先順位を変える可能性があります。予算が限られ、戦争関連の取り組みや紛争後の再建に資源を配分する必要があるため、ヘルスケア・インフラ、研究開発への投資が減少する可能性があります。

紛争が続くと、被災地での研究開発の努力が妨げられる可能性があります。不安定な研究環境とともに、資金や資源の制約が、リキッドバイオプシー技術に関する技術革新や科学的ブレークスルーの進展を遅らせる可能性があります。さらに、国際的なパートナーとの協力や知識や専門知識の交換は、紛争の中で困難に直面する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 小児固形がん患者を対象とした液体生検の調査の高まり
      • がん診断における新たなツール開発の高まり
    • 抑制要因
      • リキッドバイオプシーにおける技術的課題と限界
    • 機会
      • 研究協力の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 循環バイオマーカー別

  • 循環腫瘍細胞
  • 循環腫瘍DNA（ctDNA）
  • 無細胞DNA（cfDNA）
  • 細胞外小胞

第9章 製品・サービス別

  • キット・試薬
  • 機器
  • サービス

第10章 アプリケーション別

  • がんアプリケーション
    • 乳がん
    • 大腸がん
    • 肺がん
    • 前立腺がん
    • 肝臓がん
    • その他
  • がん以外のアプリケーション
    • 非侵襲的出生前検査（NIPT）
    • 臓器移植
    • 感染症検査

第11章 テクノロジー別

  • 多遺伝子並列解析（NGS）
  • 単一遺伝子解析（PCRマイクロアレイ）

第12章 エンドユーザー別

  • 病院および医師研究室
  • 研究センター
  • その他

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東およびアフリカ

第14章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第15章 企業プロファイル

  • Bio-Rad Laboratories
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F. Hoffmann-La Roche AG
  • Exosome Sciences Inc.
  • Grail Inc
  • Guardant Health
  • Thermo Fisher Scientific Inc.
  • Inivata Ltd
  • Illumina Inc
  • LungLife AI Inc
  • Qiagen NV

第16章 付録

目次
Product Code: CD320

Market Overview

The Global Liquid Biopsy Market reached US$ 4.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 12.3 billion by 2030. The Global Liquid Biopsy Market is expected to exhibit a CAGR of 15.4% during the forecast period 2023-2030.

Liquid biopsy is a non-invasive diagnostic technique that analyzes biomarkers in body fluids, providing insights into various diseases such as cancer. It offers advantages over traditional tissue biopsies, such as easier sample collection and real-time disease monitoring.

Furthermore, the increasing prevalence of cancer globally, advancements in genomic research and technology, increasing adoption of minimally invasive diagnostic procedures, and rising potential for early detection and monitoring of diseases are expected to drive the market over the forecast period.

Market Dynamics

Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers is Expected to Drive Liquid Biopsy Market Growth

According to National Cancer Institute Article 2023, researchers in the field of cancer are making advancements in the development of liquid biopsy tests, which have the potential to complement or even replace traditional tissue biopsies.

These tests analyze genetic and other material released by tumors into the bloodstream and other bodily fluids. Currently, liquid biopsies are being utilized to detect cancer-related genetic alterations and aid in treatment decision-making.

Scientists have expanded their research on liquid biopsies to include children with cancer, focusing on solid tumors such as Ewing sarcoma, osteosarcoma, and Wilms tumor (a kidney cancer). A recent study conducted by researchers from Children's Hospital Los Angeles (CHLA) and the University of Southern California has made progress in developing a liquid biopsy test specifically for pediatric cancer patients.

This test analyzes fragments of DNA found in blood samples and has shown promising results in diagnosing various types of solid tumors in children. The study, published in npj Precision Oncology, also indicates the potential of this test in assessing treatment response and detecting possible tumor recurrence following successful initial treatment.

The liquid biopsy test developed by the CHLA and USC researchers focuses on detecting copy number alterations using low-pass whole-genome sequencing. This method is cost-effective and can analyze multiple samples simultaneously.

While it can also detect some single-nucleotide changes, it cannot detect all of them. Unlike many liquid biopsies being developed for children, this approach and similar tests by other researchers aim to identify multiple types of cancer. Thus , the market is expected to drive over the forecast period due to the above factors.

Rising Development of New Tools in Diagnosing Cancer is Expected to Drive Liquid Biopsy Market Growth

Dr. Gavin Ha, a computational biologist at the Fred Hutchinson Cancer Center, has been awarded the 2022 National Institutes of Health Director's New Innovator Award. The $1.5 million five-year grant will support Ha's research in leveraging cell-free tumor DNA in liquid biopsies to gather valuable information for cancer diagnosis, treatment selection, and disease monitoring. Liquid biopsies, which involve analyzing DNA traces in blood samples, provide molecular insights into tumors.

While most liquid biopsy strategies focus on detecting cancer-associated changes in DNA sequence, Ha takes a different approach by investigating the factors that enable DNA fragments to persist in the bloodstream, specifically examining the protection provided by DNA packaging proteins. DNA in our cells is compactly packaged, and this packaging plays a role in gene regulation. Gene expression affects how cancer cells respond to treatments, their resistance patterns, and their potential to transform into different cancer cells.

Technical Challenges and Limitations in the Liquid Biopsy are Hampering the Growth of the Global Liquid Biopsy Market

Liquid biopsy techniques face various technical challenges that can limit their effectiveness and hinder the market growth. Some of these challenges include sensitivity and specificity, standardization, and reproducibility.

Besides, regulatory and reimbursement issues can hinder the widespread adoption of liquid biopsy tests. These challenges include regulatory approvals and reimbursement policies. Thus, from the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the liquid biopsy market. During the pandemic, there has been a decrease in routine healthcare visits, including cancer screenings and diagnostic procedures.

As a result, the demand for liquid biopsy tests may have been affected, as these tests are often used as non-invasive alternatives to traditional tissue biopsies. Reduced patient visits and diagnostic testing have likely resulted in a decline in the overall adoption and utilization of liquid biopsy technologies.

Moreover, many ongoing clinical trials related to liquid biopsy research and development have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of resources for COVID-19 management have resulted in the postponement or alteration of clinical trial timelines. This delay in research activities can impact introducing new liquid biopsy technologies and products to the market.

As the pandemic evolves and healthcare systems adapt, the liquid biopsy market is expected to recover and continue its growth trajectory, driven by advancements in technology, research, and the increasing demand for personalized and non-invasive cancer diagnostics.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had implications for various sectors, including the healthcare industry and potentially the liquid biopsy market. The war has caused substantial interruptions in impacted regions' healthcare infrastructure, particularly Ukraine. Damage to medical facilities, medical supply shortages, and the relocation of healthcare staff can all interrupt the routine operation of healthcare systems.

As resources are redirected to meet more pressing healthcare needs, this interruption may impact the availability and accessibility of numerous diagnostic tests, including liquid biopsy. Moreover, the war and its economic consequences can shift healthcare expenditures and priorities. With limited budgets and a need to allocate resources to war-related efforts and post-conflict rebuilding, there may be reduced investment in healthcare infrastructure, research, and development.

The ongoing conflict can obstruct research and development endeavors in the affected regions. Constraints on funding and resources, along with an unsettled research environment, can slow the progress of innovation and scientific breakthroughs concerning liquid biopsy technologies. Additionally, collaborating and exchanging knowledge and expertise with international partners may face challenges amidst the conflict.

Segment Analysis

The Global Liquid Biopsy Market is segmented based on circulating biomarkers, products & services, applications, technology, end user, and region.

The Kits & Reagents Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The kits & reagents segment accounted for the highest market stake, accounting for approximately 43.7% of the liquid biopsy market in 2022. Liquid biopsy kits and reagents are widely adopted worldwide. This is because liquid biopsy kits and reagents are the essential components required to collect and process samples for analysis.

These kits and reagents include specific reagents, enzymes, buffers, and other materials necessary for DNA or RNA extraction, amplification, and analysis. They are designed to provide researchers and healthcare professionals with standardized and reliable tools for liquid biopsy testing.

The increasing demand for non-invasive diagnostic methods and the growing awareness of liquid biopsy's potential in cancer detection and monitoring drives the adoption of liquid biopsy kits and reagents. These kits and reagents are readily available from various manufacturers and suppliers, making them accessible to laboratories and research institutions worldwide. Thus, owing to the above factors, the market is expected to hold the largest market share in the forecast period.

Geographical Analysis

The North American Region is Dominating the Global Liquid Biopsy Market

North America is expected to dominate the nootropics market, accounting for around 38.9%. Higher investments and numerous biotechnology businesses producing the tests, high cancer prevalence, rapid technological advancements, increasing regulatory approvals, and growing government initiatives dominate the North American region.

For instance, on May 29, 2023, Guardant Health, Inc. announced that Singapore's Health Sciences Authority (HSA) had granted regulatory approval for Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO (osimertinib).

Furthermore, on March 22, 2023, Droplet Biosciences, a biotechnology company specializing in liquid biopsy technologies, recently secured an $8 million seed investment to develop its lymph-based liquid biopsy platform further.

The investment will support the company's efforts in advancing its proprietary technology and expanding its cancer detection and monitoring capabilities. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV among others.

Why Purchase the Report?

  • To visualize the Global Liquid Biopsy Market segmentation based on the circulating biomarker, product & services, application, technology, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous liquid biopsy market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Liquid Biopsy Market Report Would Provide Approximately 77 Tables, 77 Figures And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Circulating Biomarker
  • 3.2. Snippet by Product & Services
  • 3.3. Snippet by Application
  • 3.4. Snippet by Technology
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers
      • 4.1.1.2. Rising Development of New Tools in Diagnosing Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. Technical Challenges and Limitations in the Liquid Biopsy
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Research Collaborations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Circulating Biomarker

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 8.1.2. Market Attractiveness Index, By Circulating Biomarker
  • 8.2. Circulating Tumor Cells*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Circulating Tumor DNA (ctDNA)
  • 8.4. Cell-free DNA (cfDNA)
  • 8.5. Extracellular Vesicles

9. By Product & Services

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
    • 9.1.2. Market Attractiveness Index, By Product & Services
  • 9.2. Kits & Reagents*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Instruments
  • 9.4. Services

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Cancer Applications*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Breast Cancer
    • 10.2.4. Colorectal Cancer
    • 10.2.5. Lung Cancer
    • 10.2.6. Prostate Cancer
    • 10.2.7. Liver Cancer
    • 10.2.8. Other
  • 10.3. Non-Cancer Applications
    • 10.3.1. Non-Invasive Prenatal Testing (NIPT)
    • 10.3.2. Organ Transplantations
    • 10.3.3. Infectious Disease Testing

11. By Technology

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.1.2. Market Attractiveness Index, By Technology
  • 11.2. Multi-gene-parallel Analysis (NGS)*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Single Gene Analysis (PCR Microarrays)

12. By End User

    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals and Physician Laboratories*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Research Centers
  • 12.4. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.2.8.1. The U.S.
      • 13.2.8.2. Canada
      • 13.2.8.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.3.8.1. Germany
      • 13.3.8.2. The U.K.
      • 13.3.8.3. France
      • 13.3.8.4. Italy
      • 13.3.8.5. Spain
      • 13.3.8.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.4.8.1. Brazil
      • 13.4.8.2. Argentina
      • 13.4.8.3. Rest of South America
  • 13.5. Asia Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.5.8.1. China
      • 13.5.8.2. India
      • 13.5.8.3. Japan
      • 13.5.8.4. Australia
      • 13.5.8.5. Rest of Asia Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
    • 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. Bio-Rad Laboratories*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. F. Hoffmann-La Roche AG
  • 15.3. Exosome Sciences Inc.
  • 15.4. Grail Inc
  • 15.5. Guardant Health
  • 15.6. Thermo Fisher Scientific Inc.
  • 15.7. Inivata Ltd
  • 15.8. Illumina Inc
  • 15.9. LungLife AI Inc
  • 15.10. Qiagen NV

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us